Adenovirus hexon protein antibody (A15)
Adenovirus hexon protein antibody (clone A15) is a mouse monoclonal antibody recognising the hexon protein of Adenovirus. Hexon protein is the largest and most abundant structural protein in the adenovirus capsid. This antibody is suitable for use in ELISA.
This antibody recognises hexon protein from all strains of adenovirus that have been tested, including strains 2, 3, 4, 5, 15, 31, 40 and 41.
The antibody does not cross react with Astrovirus, Campylobacter spp., Clostridium difficile, Cryptosporidium, Enterovirus, Escherichia coli, Giardia, Helicobacter pylori, HAV, Influenza type A, Influenza type B, Listeria monocytogenes, Norovirus, Respiratory syncytial virus, Rotavirus, Salmonella spp., Shigella spp., Yersinia enterocolitica.
Human Adenoviruses (HAdV) are non-enveloped, non-segmented double stranded DNA viruses, which belong to the genus Mastadenovirus within the Adenoviridae family of viruses. Human Adenoviruses have been further classified into seven species groups A- G. Since the discovery of adenovirus in human adenoid tissue in 1953, by Wallace Rowe and colleagues, more than 50 serotypes of HAdV and 70 genotypes have been identified (Cook, J).
Human adenoviruses are globally widespread and ubiquitous in the environment. HAdV can persist in the environment and are resistant to most household disinfectants. Transmission of HAdV occurs primarily via the faecal-oral route, with contaminated water and food being the primary source of infection. HAdV may also be spread through contact with contaminated surfaces and through aerosol droplets from an infected individual.
Human adenoviruses commonly cause respiratory disease but some HAdV serotypes cause gastrointestinal disease, conjunctivitis and cystitis. The clinical disease caused by HAdV infection varies depending on the HAdV type. In immunocompromised patients, HAdV infection can cause severe clinical symptoms that may lead to respiratory failure, neurological disease and death (CDC).
Currently there is no specific treatment for HAdV infection, which is mild and self-limiting in most cases, and licensed vaccines are not available for prophylactic treatment of the general public.
References
Cook J, Radke J. (2017). Mechanisms of pathogenesis of emerging adenoviruses. F1000Res. Jan 30;6:90. PMID: 28184296
Centres for Disease Control and Prevention: Adenoviruses
Product Datasheet
